Orphan Drugs Study Compares EMA's Significant Benefit With HTA's Relative Effectiveness Assessments
Executive Summary
A first of its kind study is underway to look at how the significant benefit assessment of orphan products by the European Medicines Agency compares with relative effectiveness assessments by health technology assessment bodies.